Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation - Wikidata - wikimedia - TriplyDB

Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation

Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation

http://www.wikidata.org/entity/Q34064066

about

Adaptive designs undertaken in clinical research: a review of registered clinical trials Management of traumatic haemorrhage--the US perspective Advances in damage control resuscitation and surgery: implications on the organization of future military field forces The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition Medical aspects of terrorist bombings - a focus on DCS and DCR.Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials.Coagulopathy following major trauma hemorrhage: lytic, lethal and a lack of fibrinogen Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.A controlled resuscitation strategy is feasible and safe in hypotensive trauma patients: results of a prospective randomized pilot trial.Hemostatic resuscitation in postpartum hemorrhage - a supplement to surgery.Current concepts in penetrating and blast injury to the central nervous system.Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial.Transfusion therapy in paediatric trauma patients: a review of the literature.Design of a cluster-randomized minority recruitment trial: RECRUIT.Earlier Endpoints are Required for Hemorrhagic Shock Trials Among Severely Injured Patients.Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality.Resuscitating PROPPRly.Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience.Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage-But did they in fact test the effect of hemostatic resuscitation?Functional capacity of reconstituted blood in 1:1:1 versus 3:1:1 ratios: a thrombelastometry study.Risk Factors for the Development of Acute Respiratory Distress Syndrome Following Hemorrhage.Outcomes after concomitant traumatic brain injury and hemorrhagic shock: A secondary analysis from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios trial.Damage control resuscitation using blood component therapy in standard doses has a limited effect on coagulopathy during trauma hemorrhage.Protecting study participants in emergency research: is community consultation before trial commencement enough?Protocol for a pilot randomized controlled trial comparing plasma with balanced crystalloid resuscitation in surgical and trauma patients with septic shock

P2860

Q26753245-22FD39DC-7D53-498A-945C-5650B8C6AB34 Q26995494-A43F5CC2-8E6F-4941-A319-4ADA762DE9BA Q27024280-BD971FAF-A5A1-437D-ACE9-13112C301499 Q27339343-2798E24E-DEE1-4BD6-B81C-9170E85D6F12 Q30204597-10A20756-648D-458A-B8CD-6B7984CF652B Q30666196-C7A13968-BDB5-4947-9D4B-653DC2A77FAB Q33822672-A9815984-E3B4-41D1-BE60-DDE1A4F4D306 Q35219638-D5D3CA51-6F92-4FC5-B65C-9BC65937854D Q35222649-2FF36F66-5D9E-4E58-8669-B3421CBB3826 Q35557436-9B123ED5-49E6-4030-9033-B1A946D0B5F4 Q35578086-865E4DBE-AE5F-4B42-8992-524F8CAD27BB Q35748687-DEFF25A5-1F97-42D6-9E07-02129120890E Q38427221-482D0612-F2AB-44C8-8EC1-BEA3242FCC17 Q38763336-C1137376-87AB-4DDB-B86A-A614008EFBA1 Q38957510-58BAC475-D4D8-4553-BC12-58F3950CD2C7 Q40223619-27B0E2A8-CAF8-431C-A731-1C655BA4C4AB Q41096308-4360F45F-6403-4B64-A2A8-43F53A2BE1AC Q41644019-A73D5610-4CD6-4CB7-9A32-96BD5D4EDF3C Q42344570-51E17C97-C0EE-45B4-9FCF-AE096B6746AF Q43108387-1F7F1CBA-4810-4FC9-A75A-D600BC2BBE8F Q46932097-F781D5EC-4CDA-4364-B340-7C323A2FA358 Q47295515-ED9F3055-9F30-4843-BFA3-333CA885B1D8 Q50456307-C0CB5988-FC9D-4A0A-98C3-44D201F2D82E Q56763360-474FC8E1-7DC2-4FD8-808D-E161B91B7C50 Q57070718-E202C397-CA6B-425F-80DF-509E69E4E6AA

P2860

Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation

http://www.wikidata.org/entity/Q34064066

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Pragmatic Randomized Optimal P ...... , rationale and implementation

@ast

Pragmatic Randomized Optimal P ...... , rationale and implementation

@en

Pragmatic Randomized Optimal P ...... , rationale and implementation

@nl

type

label

Pragmatic Randomized Optimal P ...... , rationale and implementation

@ast

Pragmatic Randomized Optimal P ...... , rationale and implementation

@en

Pragmatic Randomized Optimal P ...... , rationale and implementation

@nl

prefLabel

Pragmatic Randomized Optimal P ...... , rationale and implementation

@ast

Pragmatic Randomized Optimal P ...... , rationale and implementation

@en

Pragmatic Randomized Optimal P ...... , rationale and implementation

@nl

P1433

Q34064066-392EA568-6240-48C7-ADD7-D0E05582BF07

P1476

Q34064066-8F050A6F-E7FD-4C55-82D2-F94467261818

P2093

Q34064066-0B49542D-9104-49DC-97D7-1580A1FCA857

Q34064066-27108554-4F98-4EE7-BA75-28BCE4F6FFED

Q34064066-2F266906-0EAD-4B44-877C-CE48B4DAAC02

Q34064066-443A253E-AC10-4B02-84B1-DE05B4E6C41A

Q34064066-69B4B42F-42DE-4900-B1DB-A81DF295BDC0

Q34064066-6B7879AF-A714-4ED0-AA44-C582FCB4A611

Q34064066-7048EBB8-155C-48BF-AFFD-85E6DADF5C15

Q34064066-734F84E2-75F2-4AE7-A595-9B9F2A05ADFA

Q34064066-7921553D-8243-4CAD-8528-ED76C71F124F

Q34064066-7ADC4386-2B17-45FA-B307-AA135897D486

P2860

Q34064066-05197D3D-F2C4-47EE-BF00-58C13FC00393

Q34064066-13D385FB-2EA1-4D06-97BE-31134851A9F7

Q34064066-152BFD4F-A289-452E-8358-185BBCD37550

Q34064066-159E3815-3316-453F-893B-B0567802B6BC

Q34064066-20A4DBCF-0428-48C6-BADD-5DC837CEC908

Q34064066-2239C54A-1E46-4AF5-888B-7598ED1F221D

Q34064066-2497F7E4-AA18-4716-A501-9AF1B9387B8A

Q34064066-2BFEC0FE-2045-4694-8B09-6D26441DF57D

Q34064066-3360BF5E-71DB-4570-8A50-E77986D4F3D9

Q34064066-35740F3C-029C-4D8A-A7E6-D6D0F66D3AA9

P304

Q34064066-0D4F5581-63CC-491B-A927-992F76C8008D

P31

Q34064066-AFB5B0E3-F8C2-4D34-926C-1293933B42C5

P356

Q34064066-CE32DB7F-3BD0-4E29-8738-51AA3567D394

P433

Q34064066-B7DDD3F8-5587-4B31-A488-590AAFB16C1D

P478

Q34064066-29B1F01C-A38A-41F0-A940-75492441B667

P50

Q34064066-35D31D9D-C298-46EE-9237-3011C3779EED

Q34064066-71EF2C40-A5D2-481E-AFE6-F9B43C4A186D

Q34064066-EA34008F-B554-459C-B268-2D0F78BE43F2

P577

Q34064066-D1A4CCB1-4969-4EBB-AEBF-CEE74DA683A7

P5875

Q34064066-0364362C-CE56-46D7-BFF9-538BF09708B9

P698

Q34064066-C34744FF-F66A-476E-B282-56E30A94D577

P932

Q34064066-A7E0FE5D-BF11-436A-A23E-F33EDE79C269

P356

J.INJURY.2014.06.001

P1433

P1476

Pragmatic Randomized Optimal P ...... , rationale and implementation

@en

P2093

Angela M Beeler

http://www.w3.org/2001/XMLSchema#string

Barbara C Tilley

http://www.w3.org/2001/XMLSchema#string

Bryan A Cotton

http://www.w3.org/2001/XMLSchema#string

Charles E Wade

http://www.w3.org/2001/XMLSchema#string

Christopher N Miller

http://www.w3.org/2001/XMLSchema#string

Deborah J del Junco

http://www.w3.org/2001/XMLSchema#string

Eileen M Bulger

http://www.w3.org/2001/XMLSchema#string

Erin E Fox

http://www.w3.org/2001/XMLSchema#string

Gerald van Belle

http://www.w3.org/2001/XMLSchema#string

Jeanette M Podbielski

http://www.w3.org/2001/XMLSchema#string

P2860

A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers

Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004

The epidemiology and modern management of traumatic hemorrhage: US and international perspectives

A multiple testing procedure for clinical trials

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.

The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks

The random dialing survey as a tool for community consultation for research involving the emergency medicine exception from informed consent.

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

P304

1287-1295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.INJURY.2014.06.001

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Terence O'Keeffe

Timothy C Fabian

P577

2014-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264643455

http://www.w3.org/2001/XMLSchema#string

P698

24996573

http://www.w3.org/2001/XMLSchema#string

P932

4137482

http://www.w3.org/2001/XMLSchema#string